###begin article-title 0
###xml 34 35 34 35 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 39 43 39 43 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2/3 </sub>
###xml 70 74 <span type="species:ncbi:10116">rats</span>
Inhibitory role of supraspinal P2X3/P2X2/3 subtypes on nociception in rats
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin p 2
###xml 303 305 303 305 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 738 740 738 740 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 747 751 747 751 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2/3 </sub>
###xml 940 942 933 935 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1049 1051 1042 1044 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1234 1242 1220 1228 <underline xmlns:xlink="http://www.w3.org/1999/xlink">enhanced</underline>
###xml 1436 1437 1422 1423 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1441 1445 1427 1431 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2/3 </sub>
###xml 897 901 <span type="species:ncbi:10116">rats</span>
Extracellular ATP is known to mediate synaptic transmission as a neurotransmitter or a neuromodulator via ionotropic P2X and metabotropic P2Y receptors. Several lines of evidence have suggested that ATP facilitates pain transmission at peripheral and spinal sites via the P2X receptors, in which the P2X3 subtype is considered as an important candidate for the effect. Conversely, we previously found that the activation of supraspinal P2X receptors evoked antinociception. However, the subtypes responsible for the antinociception via supraspinal P2X receptors remain unclear. In the present study, we showed that intracerebroventricular (i.c.v.) pretreatment with A-317491 (1 nmol), the novel non-nucleotide antagonist selective for P2X3 and P2X2/3 receptors, attenuated the antinociceptive effect produced by i.c.v. administered alpha,beta-methylene-ATP (10 nmol), the P2X receptor agonist, in rats. Similarly, the abolishment of the P2X3 receptor mRNA in the brainstem by repeated i.c.v. pretreatments with antisense oligodeoxynucleotide for P2X3 gene once a day for 5 consecutive days diminished the antinociceptive effect of alpha,beta-methylene-ATP. Furthermore, i.c.v. administration of A-317491 (1 and 10 nmol) significantly enhanced the inflammatory nociceptive behaviors induced by the intraplantar injection of formalin and intraperitoneal injection of acetic acid. Taken together, these results suggest that supraspinal P2X3/P2X2/3 receptors play an inhibitory role in pain transmission.
###end p 2
###begin title 3
Findings
###end title 3
###begin p 4
###xml 129 131 129 131 <sub xmlns:xlink="http://www.w3.org/1999/xlink">n </sub>
###xml 138 139 138 139 <sub xmlns:xlink="http://www.w3.org/1999/xlink">n</sub>
###xml 193 194 193 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 195 196 195 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 320 321 320 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 322 323 322 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 398 400 398 400 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 543 544 543 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 545 546 545 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 644 646 644 646 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 661 665 661 665 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2/3 </sub>
###xml 750 751 750 751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 752 754 752 754 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 805 807 805 807 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 814 818 814 818 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2/3 </sub>
###xml 1228 1230 1228 1230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1231 1233 1231 1233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1406 1407 1406 1407 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1411 1415 1411 1415 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2/3 </sub>
###xml 1544 1545 1544 1545 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1549 1553 1549 1553 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2/3 </sub>
###xml 1564 1566 1564 1566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1567 1569 1567 1569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1597 1599 1597 1599 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1768 1769 1768 1769 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1773 1777 1773 1777 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2/3 </sub>
###xml 1712 1817 1712 1817 <underline xmlns:xlink="http://www.w3.org/1999/xlink">the endogenous purinergic system through supraspinal P2X<sub>3</sub>/P2X<sub>2/3 </sub>receptors in the exacerbated pain states</underline>
###xml 1127 1131 <span type="species:ncbi:10116">rats</span>
###xml 1667 1671 <span type="species:ncbi:10116">rats</span>
Extracellular ATP has been established as a signaling molecule that mediates diverse biological effects via P2 purinoceptors (P2Xn and P2Yn) in both the peripheral and central nervous systems [1,2]. A body of evidence indicates that ionotropic P2X receptors are involved in both peripheral and spinal pain transmission [3-5]. Of the seven P2X receptors identified to date, the expression of the P2X3 receptors appear selective for a subpopulation of small-diameter dorsal root ganglion neurons, which are probably associated with nociception [6-8]. In vivo studies have provided evidence that the activation of P2X receptors, especially the P2X3 subtype and P2X2/3 heteromer, contributes to an acute nociceptive behavior, hyperalgesia and allodynia [9-12]. These observations support the idea that the P2X3 and P2X2/3 receptors play a crucial role in facilitating pain transmission at the peripheral and spinal sites. On the other hand, at the supraspinal level, we previously reported that the intracerebroventricular (i.c.v.) administration of ATP and P2X receptor agonists produced mechanical and thermal antinociception in rats, suggesting that supraspinal P2X receptors play an inhibitory role in nociceptive transmission [13-15]. However, it remains unclear what subtypes of supraspinal P2X receptors are involved in the antinociceptive effect. In the present study, to clarify the involvement of P2X3/P2X2/3 receptors, we investigated the effect of i.c.v. pretreatment with A-317491, the novel non-nucleotide antagonist selective for P2X3/P2X2/3 receptors [16,17] and down-regulation of P2X3 receptors in the brain by antisense oligodeoxynucleotide (A-ODN) in rats. Furthermore, to determine the roles of the endogenous purinergic system through supraspinal P2X3/P2X2/3 receptors in the exacerbated pain states, we examined the effect of A-317491 administered i.c.v. on the inflammatory nociceptive behaviors induced by chemical agents.
###end p 4
###begin p 5
###xml 332 334 332 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 5 24 <span type="species:ncbi:10116">Sprague-Dawley rats</span>
Male Sprague-Dawley rats weighing 180-250 g were used. The experiments were conducted in accordance with the ethical guidelines of the Kyoto University animal experimentation committee, and the guidelines of the Japanese Pharmacological Society. The surgery for i.c.v. administration was conducted according to our previous report [13]. After surgery, the animals were returned to cages and housed individually, being allowed to recover for 5 to 7 days until the experiments started. The i.c.v. injection was carried out in a volume of 5 mul at a constant rate of 5 mul/30 sec.
###end p 5
###begin p 6
###xml 144 146 144 146 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 194 195 194 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 761 763 758 760 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 137 140 <span type="species:ncbi:10116">rat</span>
The 20-base A-ODN endcapped with phosphorothioate linkages (Nisshinbo Inc, Japan) were designed according to the primary sequence of the rat P2X3 receptor cDNA (X91167) as previously described [9]. The sequence of A-ODN was 5'-T*G*AA*GAAGTCTGATATAC*A*G-3', while the sequence of sense oligodeoxynucleotide (S-ODN) served as a control was 5'-C*T*GTATATCAGACTTCTT*C*A-3' (* as phosphorothioate). A-ODN and S-ODN were dissolved in PBS. I.c.v. injection of PBS (5 mul), A-ODN (1 nmol/5 mul), or S-ODN (1 nmol/5 mul) was carried out once a day for 5 consecutive days, and the behavioral assessment was conducted on next day of the last injection. After the behavioral test, the brain was removed, and the brainstem sample was dissected. Then, the mRNA levels for P2X3 receptor and beta-actin in the brainstem were analyzed using an RT-PCR method.
###end p 6
###begin p 7
###xml 139 141 132 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 142 144 135 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 669 671 655 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 672 674 658 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
The antinociceptive effect of alpha,beta-methylene-ATP administered i.c.v. was measured by the paw pressure test, as previously described [13,14]. Briefly, using an analgesimeter (Ugo Basile, Milan, Italy), the cuneate piston was put on the right hind paw and the pressure was loaded at a rate of 32 g/sec. The pressure that elicited paw withdrawal behavior, was determined as the nociceptive threshold. After several habituation procedures, alpha,beta-methylene-ATP (Sigma, St. Louis, MO) dissolved in PBS was administered i.c.v. at a dose of 10 nmol, and the nociceptive threshold was measured 5 min after the i.c.v. administration according to our previous reports [13,14]. Nociceptive behaviors evoked by inflammatory stimuli using formalin and acetic acid were assessed. For the measurement of formalin-induced nociceptive behavior, scoring of nociceptive behavior started immediately after the intraplantar (i.pl.) injection of 2% formalin at a volume of 100 mul into the right hindpaw. The nociceptive behaviors were observed for 60 min and were quantified using a rating scale method by assigning weights to the following categories: the injected paw was elevated, and was not in contact with the floor (weight = 1); and the injected paw was licked, bitten, or shaken (weight = 2). The time an animal spent in each behavioral category was multiplied by the category weight (1 or 2), summed, and then divided by the total test session period (300 sec). For the measurement of acetic acid-induced nociceptive writhing behavior, counting the number of typical writhing behaviors, characterized by a wave of contraction of the abdominal musculature followed by extension of the hind limbs, started immediately after the intraperitoneal (i.p.) injection of 2% acetic acid at a volume of 1 ml. The writhing behavior was observed for 60 min and the number of occurrences every 5 min was evaluated.
###end p 7
###begin p 8
###xml 126 135 126 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">post hoc </italic>
###xml 156 158 156 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
The statistical significance was calculated using one-way or two-way analysis of variance (ANOVA), followed by the Bonferroni post hoc test. Differences at P < 0.05 were considered significant.
###end p 8
###begin p 9
###xml 162 164 155 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 361 363 347 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 485 486 471 472 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 486 491 472 477 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5,29 </sub>
###xml 499 501 485 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 627 629 613 615 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
The effect of i.c.v. pretreatment with A-317491 (Sigma) on the antinociceptive effect produced by i.c.v. administered alpha,beta-methylene-ATP was examined (Fig. 1A). I.c.v. administration of alpha,beta-methylene-ATP (10 nmol) at 15 min after i.c.v. pretreatment with PBS produced a significant antinociceptive effect, compared with the PBS-administered group (P < 0.001). The antinociceptive effect was dose-dependently and significantly reduced by i.c.v. pretreatment with A-317491 (F5,29 = 9.43, P < 0.001). The significant inhibitory effect of A-317491 was observed at a dose of 1 nmol, compared with PBS-pretreated group (P < 0.05). A-317491 (1 nmol) itself had no effect on the nociceptive threshold.
###end p 9
###begin p 10
###xml 34 35 34 35 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 39 43 39 43 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2/3 </sub>
###xml 0 137 0 130 <bold xmlns:xlink="http://www.w3.org/1999/xlink">The involvement of supraspinal P2X<sub>3</sub>/P2X<sub>2/3 </sub>receptors in the antinociception produced by i.c.v. administration of &#945;,&#946;-methylene-ATP</bold>
###xml 653 655 630 632 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 681 682 658 659 <sup xmlns:xlink="http://www.w3.org/1999/xlink">#</sup>
###xml 682 684 659 661 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 730 732 700 702 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 797 799 767 769 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 906 908 873 875 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 931 933 898 900 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1011 1013 978 980 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1026 1028 993 995 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1107 1109 1067 1069 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1117 1119 1077 1079 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
The involvement of supraspinal P2X3/P2X2/3 receptors in the antinociception produced by i.c.v. administration of alpha,beta-methylene-ATP. The nociceptive thresholds at 5 min after the i.c.v. administration of alpha,beta-methylene-ATP (10 nmol) were compared in the paw pressure test. The nociceptive threshold of each animal before the i.c.v. administration served as the control value (100%), and the values are presented as the means of the % of the control +/- S.E.M. (A) The effect of i.c.v. pretreatment with A-317491. alpha,beta-Methylene-ATP or PBS was administered i.c.v. 15 min after i.c.v. pretreatment with A-317491 (0.01-1 nmol) or PBS. ***P < 0.001 vs PBS-PBS group, #P < 0.05 vs PBS-alpha,beta-methylene-ATP group (n = 5-8). (B) RT-PCR analyses of the mRNA expression levels for P2X3 receptor (upper) and beta-actin (bottom) in the brainstem after repeated i.c.v. pretreatments with PBS, P2X3 A-ODN (1 nmol), and P2X3 S-ODN (1 nmol). (C) The effects of repeated i.c.v. pretreatments with PBS, P2X3 A-ODN and P2X3 S-ODN on the antinociception by i.c.v. administered alpha,beta-methylene-ATP. *P < 0.05 (n = 5-6).
###end p 10
###begin p 11
###xml 0 28 0 28 <underline xmlns:xlink="http://www.w3.org/1999/xlink">In the rat i.c.v. pretreated</underline>
###xml 56 58 56 58 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 86 88 86 88 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 202 204 202 204 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 216 218 216 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 259 261 259 261 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 504 506 497 499 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 513 514 506 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 514 519 507 512 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2,14 </sub>
###xml 527 529 520 522 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 572 574 565 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 589 591 582 584 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 609 611 602 604 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 632 634 625 627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1C</xref>
###xml 7 10 <span type="species:ncbi:10116">rat</span>
###xml 228 231 <span type="species:ncbi:10116">rat</span>
In the rat i.c.v. pretreated repeatedly with PBS and P2X3 S-ODN, the expression of P2X3 receptor mRNA in the brainstem was observed, while it was diminished by the repeated i.c.v. pretreatments with P2X3 A-ODN (Fig. 1B). In the rat pretreated with PBS and P2X3 S-ODN, i.c.v. administration of alpha,beta-methylene-ATP (10 nmol) produced an antinociceptive effect, and there was no difference between them. The antinociceptive effect was significantly reduced by the repeated i.c.v. pretreatments with P2X3 A-ODN (F2,14 = 6.61, P < 0.01), compared with the PBS-pretreated (P < 0.05) and P2X3 S-ODN-pretreated (P < 0.05) groups (Fig. 1C).
###end p 11
###begin p 12
###xml 39 40 39 40 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 44 48 44 48 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2/3 </sub>
###xml 24 57 24 57 <underline xmlns:xlink="http://www.w3.org/1999/xlink">supraspinal P2X<sub>3</sub>/P2X<sub>2/3 </sub>receptors</underline>
###xml 235 236 235 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 468 469 468 469 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 469 475 469 475 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2,168 </sub>
###xml 483 485 483 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 683 684 683 684 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 684 690 684 690 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2,168 </sub>
###xml 698 700 698 700 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
To clarify the roles of supraspinal P2X3/P2X2/3 receptors in inflammatory pain, we examined the effect of the i.c.v. administration of A-317491 on inflammatory nociceptive behaviors induced by i.pl. formalin and i.p. acetic acid (Fig. 2). The i.pl. injection of formalin produced characteristic biphasic nociceptive behaviors. The i.c.v. administration of A-317491 (1 and 10 nmol) 5 min before the formalin injection significantly increased the nociceptive behaviors (F2,168 = 6.07, P < 0.01). Similarly, the number of acetic acid-induced writhing behaviors was significantly increased by the i.c.v. administration of A-317491 (1 and 10 nmol) 5 min before the acetic acid injection (F2,168 = 6.73, P < 0.01).
###end p 12
###begin p 13
###xml 0 89 0 89 <bold xmlns:xlink="http://www.w3.org/1999/xlink">The effect of i.c.v. administration of A-317491 on the inflammatory nociceptive behaviors</bold>
###xml 907 909 905 907 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 920 922 918 920 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 943 945 941 943 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
The effect of i.c.v. administration of A-317491 on the inflammatory nociceptive behaviors. (A) For the measurement of formalin-induced nociceptive behavior, the scoring of nociceptive behavior started immediately after the i.pl. injection of formalin into the right hindpaw. The nociceptive behaviors were observed for 60 min and were quantified using a rating scale method by assigning weights for each 5 min. (B) For the measurement of acetic acid-induced nociceptive writhing behavior, counting the number of typical writhing behaviors started immediately after the i.p. injection of acetic acid. The writhing behavior was observed for 60 min and the number of occurrences every 5 min was evaluated. The i.c.v. administration of A-317491 (1 and 10 nmol) or PBS was performed 5 min before the i.pl. injection of formalin or i.p. injection of acetic acid. The values are presented as the means +/- S.E.M. *P < 0.05, ***P < 0.05 vs PBS group (n = 5-6).
###end p 13
###begin p 14
###xml 44 46 44 46 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 56 60 56 60 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2/3 </sub>
###xml 41 69 41 69 <underline xmlns:xlink="http://www.w3.org/1999/xlink">P2X<sub>3 </sub>and/or P2X<sub>2/3 </sub>receptors</underline>
###xml 181 183 181 183 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 190 194 190 194 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2/3 </sub>
###xml 261 311 261 311 <underline xmlns:xlink="http://www.w3.org/1999/xlink">in rat models of inflammatory and neuropathic pain</underline>
###xml 312 314 312 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 315 317 315 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 475 476 468 469 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 481 483 474 476 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 490 494 483 487 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2/3 </sub>
###xml 449 503 442 496 <underline xmlns:xlink="http://www.w3.org/1999/xlink">which is selective for P2X<sub>1</sub>, P2X<sub>3 </sub>and P2X<sub>2/3 </sub>receptors</underline>
###xml 554 555 547 548 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 559 563 552 556 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2/3 </sub>
###xml 609 611 602 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 612 614 605 607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 624 626 617 619 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 880 882 873 875 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 883 885 876 878 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 901 903 894 896 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 972 974 965 967 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1121 1123 1107 1109 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1177 1179 1163 1165 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1290 1291 1276 1277 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1207 1442 1193 1428 <underline xmlns:xlink="http://www.w3.org/1999/xlink">In the the nucleus of the solitary tract, the ultrastructural study showed that P2X<sub>3</sub>-immunoreactive boutons synapsed on dendrites and cell bodies, and had complex synaptic interaction with other axon terminals and vesiculated dendrites</underline>
###xml 1443 1445 1429 1431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1563 1565 1542 1544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1566 1568 1545 1547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1718 1772 1690 1744 <underline xmlns:xlink="http://www.w3.org/1999/xlink">by co-injection with the P2X receptor antagonist PPADS</underline>
###xml 1773 1775 1745 1747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1820 1822 1792 1794 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1848 1850 1820 1822 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 264 267 <span type="species:ncbi:10116">rat</span>
###xml 697 700 <span type="species:ncbi:10116">rat</span>
The present study provides evidence that P2X3 and/or P2X2/3 receptors are responsible for supraspinal P2X receptor-mediated antinociception. A-317491, a selective antagonist for P2X3 and P2X2/3 receptors, produces antinociception at peripheral and spinal sites in rat models of inflammatory and neuropathic pain[16-19]. Conversely, we found that the acute i.c.v. injection of A-317491 blocked the antinociceptive effect of alpha,beta-methylene-ATP, which is selective for P2X1, P2X3 and P2X2/3 receptors, suggesting that the activation of supraspinal P2X3/P2X2/3 receptors exerted the antinociceptive effect [16,17]. The P2X3 subtype expressed in the brain is primarily distributed throughout the rat hindbrain, including the nucleus of the solitary tract, medial vestibular nucleus, medial and lateral parabrachial nuclei, rostral ventrolateral medulla and locus coeruleus (LC) [20,21], while the P2X2 subtype is widely distributed in the brain, including the hindbrain [22]. Therefore, it is assumed that the decreased effect of alpha,beta-methylene-ATP-induced antinociception by repeated i.c.v. pretreatments with P2X3 A-ODN is attributed to the decreased expression of P2X3 receptors in the hindbrain. In the the nucleus of the solitary tract, the ultrastructural study showed that P2X3-immunoreactive boutons synapsed on dendrites and cell bodies, and had complex synaptic interaction with other axon terminals and vesiculated dendrites[20]. It is also described that alpha,beta-methylene-ATP excites the neurons arising from the hindbrain, such as the LC [23,24]. We previously found that the bilateral microinjection of alpha,beta-methylene-ATP into the LC produced robust antinociception, which was inhibited by co-injection with the P2X receptor antagonist PPADS[15], suggesting that the decreased level of P2X3 receptors in the LC by P2X3 A-ODN might have resulted in the blockade of alpha,beta-methylene-ATP-induced antinociception.
###end p 14
###begin p 15
###xml 417 419 417 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 454 456 454 456 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 533 534 533 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 535 537 535 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 861 862 861 862 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 866 870 866 870 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2/3 </sub>
###xml 1378 1380 1371 1373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1442 1444 1435 1437 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 1654 1656 1647 1649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 1659 1874 1652 1867 <underline xmlns:xlink="http://www.w3.org/1999/xlink">These findings support the possibility that the inflammatory pain, but not acute pain, might stimulate the release of endogenous ATP into the extracellular space at the supraspinal level, as well as the spinal level</underline>
###xml 1875 1877 1868 1870 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1878 1880 1871 1873 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1881 1883 1874 1876 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
There are several lines of evidence that endogenous ATP appears to play a facilitatory role in pain transmission at the peripheral and spinal levels, which is consistent with the effect of the exogenous injection of ATP and P2X receptor agonists. For instance, it has been reported that the intrathecal injection of PPADS attenuated the nociceptive behaviors induced by the i.pl. injection of formalin and capsaicin [25]. The intrathecal injection of P2X3 A-ODN also attenuated the hyperalgesia and allodynia after the nerve injury [9-11], however, the role of endogenous ATP in a supraspinal pain transmission has been unclear. Our present study found that i.c.v. administration of A-317491 deteriorated the inflammatory pain induced by formalin and acetic acid, suggesting that the endogenous ATP also plays an inhibitory role in pain transmission through P2X3/P2X2/3 receptors at the supraspinal level. The effect of A-317491 was rapidly normalized to the controlled level in both formalin- and acetic acid-induced inflammatory nociceptive behaviors. It is consistent with our previous findings that the antinociceptive effect by i.c.v. administered alpha,beta-methylene-ATP was rapid and short lasting. The rapid effect of A-317491 is not probably due to the enzymatic degradation, as it is reported that A-317491 induces a long-lasting effect following systemic injection [16]. This might have resulted from the characteristic of the P2X3 receptor, which is known to be rapidly desensitized following its activation. Nevertheless, the i.c.v. injection of A-317491 did not affect the baseline nociceptive threshold in the paw pressure test (see Fig. 1A). These findings support the possibility that the inflammatory pain, but not acute pain, might stimulate the release of endogenous ATP into the extracellular space at the supraspinal level, as well as the spinal level[18,26,27].
###end p 15
###begin p 16
###xml 75 76 75 76 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 80 84 80 84 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2/3 </sub>
Taken together, our findings suggest that the activation of supraspinal P2X3/P2X2/3 receptors produces antinociception. Since the effect at the supraspinal site is opposed to that at peripheral and spinal sites, further study might be needed to understand their role at the supraspinal site to develop potential analgesics via these receptors. Moreover, our results indicate that endogenous ATP at the supraspinal site plays an inhibitory role in the early stage of inflammatory pain.
###end p 16
###begin title 17
Abbreviations
###end title 17
###begin p 18
ATP: adenosine 5'-triphosphate
###end p 18
###begin p 19
A-317491: (5-({(3-phenoxybenzyl) [(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]amino}-carbonyl)-1,2,4-benzenetricarboxylic acid)
###end p 19
###begin p 20
PBS: phosphate-buffered saline
###end p 20
###begin p 21
PPADS: pyridoxal-phosphate-6-azophenyl-2',4'-disulphonic acid
###end p 21
###begin p 22
RT-PCR: reverse transcriptase-polymerase chain reaction
###end p 22
###begin title 23
Competing interests
###end title 23
###begin p 24
The author(s) declare that they have no competing interests.
###end p 24
###begin title 25
Authors' contributions
###end title 25
###begin p 26
MF carried out all the studies outlined in the manuscript, participated in the design of the studies and wrote the initial draft of the manuscript. TN conceived the study, participated in the design and the coordination of the study, performed statistical analysis, and wrote the final draft of the manuscript. MM participated in the design and coordination of the study. MS and SK supervised the experiments. All authors read and approved the final manuscript.
###end p 26
###begin title 27
Acknowledgements
###end title 27
###begin p 28
This work was partly supported by grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan.
###end p 28
###begin article-title 29
Receptors for purines and pyrimidines
###end article-title 29
###begin article-title 30
Involvement of P2 receptors in the growth and survival of neurons in the CNS
###end article-title 30
###begin article-title 31
A unifying purinergic hypothesis for the initiation of pain
###end article-title 31
###begin article-title 32
P2X receptors and nociception
###end article-title 32
###begin article-title 33
Neuropathic pain and spinal microglia: a big problem from molecules in 'small' glia
###end article-title 33
###begin article-title 34
A P2X purinoceptor expressed by a subset of sensory neurons
###end article-title 34
###begin article-title 35
###xml 19 21 19 21 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 28 30 28 30 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
Coexpression of P2X2 and P2X3 receptor subunits can account for ATP-gated currents in sensory neurons
###end article-title 35
###begin article-title 36
###xml 3 5 3 5 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
P2X3 is expressed by DRG neurons that terminate in inner lamina II
###end article-title 36
###begin article-title 37
###xml 21 23 21 23 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 74 79 <span type="species:ncbi:10090">mouse</span>
Downregulation of P2X3 receptor-dependent sensory functions in A/J inbred mouse strain
###end article-title 37
###begin article-title 38
###xml 32 34 32 34 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 54 57 <span type="species:ncbi:10116">rat</span>
Functional downregulation of P2X3 receptor subunit in rat sensory neurons reveals a significant role in chronic neuropathic and inflammatory pain
###end article-title 38
###begin article-title 39
###xml 36 38 36 38 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 129 133 <span type="species:ncbi:10116">rats</span>
Analgesic profile of intrathecal P2X3 antisense oligonucleotide treatment in chronic inflammatory and neuropathic pain states in rats
###end article-title 39
###begin article-title 40
siRNA relieves chronic neuropathic pain
###end article-title 40
###begin article-title 41
###xml 98 101 <span type="species:ncbi:10116">rat</span>
Antinociceptive effects of intracerebroventricularly administered P2 purinoceptor agonists in the rat
###end article-title 41
###begin article-title 42
###xml 19 20 16 17 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Involvement of beta2-adrenergic and mu-opioid receptors in antinociception produced by intracerebroventricular administration of alpha,beta-methylene-ATP
###end article-title 42
###begin article-title 43
###xml 115 119 <span type="species:ncbi:10116">rats</span>
Involvement of locus coeruleus noradrenergic neurons in supraspinal antinociception by alpha,beta-methylene-ATP in rats
###end article-title 43
###begin article-title 44
###xml 71 73 71 73 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 80 84 80 84 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2/3 </sub>
###xml 152 155 <span type="species:ncbi:10116">rat</span>
A-317491, a novel potent and selective non-nucleotide antagonist of P2X3 and P2X2/3 receptors, reduces chronic inflammatory and neuropathic pain in the rat
###end article-title 44
###begin article-title 45
###xml 1 2 1 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 96 100 96 100 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2/3 </sub>
###xml 107 109 107 109 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 87 92 <span type="species:ncbi:9606">human</span>
[3H]A-317491, a novel high-affinity non-nucleotide antagonist that specifically labels human P2X2/3 and P2X3 receptors
###end article-title 45
###begin article-title 46
###xml 46 47 46 47 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 51 55 51 55 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2/3 </sub>
Effects of A-317491, a novel and selective P2X3/P2X2/3 receptor antagonist, on neuropathic, inflammatory and chemogenic nociception following intrathecal and intraplantar administration
###end article-title 46
###begin article-title 47
###xml 25 26 25 26 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 30 34 30 34 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2/3 </sub>
###xml 143 147 <span type="species:ncbi:10116">rats</span>
A-317491, a selective P2X3/P2X2/3 receptor antagonist, reverses inflammatory mechanical hyperalgesia through action at peripheral receptors in rats
###end article-title 47
###begin article-title 48
###xml 35 37 35 37 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 50 53 <span type="species:ncbi:10116">rat</span>
Ultrastructural localization of P2X3 receptors in rat sensory neurons
###end article-title 48
###begin article-title 49
###xml 53 54 53 54 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 58 60 58 60 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6 </sub>
###xml 139 157 139 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Callithrix Jacchus</italic>
###xml 110 113 <span type="species:ncbi:10116">rat</span>
###xml 122 137 <span type="species:ncbi:9483">common marmoset</span>
Comparative study on the distribution patterns of P2X1-P2X6 receptor immunoreactivity in the brainstem of the rat and the common marmoset (Callithrix Jacchus): association with catecholamine cell groups
###end article-title 49
###begin article-title 50
###xml 23 25 23 25 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 79 82 <span type="species:ncbi:10116">rat</span>
Distribution of the P2X2 receptor subunit of the ATP-gated ion channels in the rat central nervous system
###end article-title 50
###begin article-title 51
###xml 18 21 <span type="species:ncbi:10116">rat</span>
Depolarization of rat locus coeruleus neurons by adenosine 5'-triphosphate
###end article-title 51
###begin article-title 52
###xml 85 88 <span type="species:ncbi:10116">rat</span>
Role of ATP in fast excitatory synaptic potentials in locus coeruleus neurons of the rat
###end article-title 52
###begin article-title 53
###xml 133 137 <span type="species:ncbi:10090">mice</span>
Evidence for the involvement of spinal endogenous ATP and P2X receptors in nociceptive responses caused by formalin and capsaicin in mice
###end article-title 53
###begin article-title 54
ATP is a mediator of chemosensory transduction in the central nervous system
###end article-title 54
###begin article-title 55
Adenosine in the spinal cord and periphery: release and regulation of pain
###end article-title 55

